NCT02625922 - Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 5, 2016

Primary Completion Date

January 11, 2017

Study Completion Date

January 11, 2017

Conditions

Chronic Heart Failure

Interventions

DRUG

Serelaxin

Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen

DRUG

Placebo

Matching placebo i.v infusion

Trial Locations (9)

Novartis Investigative Site, Basel

Novartis Investigative Site, Berlin

Novartis Investigative Site, Greifswald

Novartis Investigative Site, München

Novartis Investigative Site, München

Novartis Investigative Site, Dresden

Novartis Investigative Site, Hull

Novartis Investigative Site, London

Novartis Investigative Site, Tyne and Wear